Last reviewed · How we verify
ALKS 37
ALKS 37 is a dual GABA_A receptor agonist.
ALKS 37 is a dual GABA_A receptor agonist. Used for Treatment-resistant schizophrenia.
At a glance
| Generic name | ALKS 37 |
|---|---|
| Sponsor | Alkermes, Inc. |
| Drug class | GABA_A receptor agonist |
| Target | GABA_A receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
ALKS 37 works by activating GABA_A receptors, which are involved in regulating neuronal excitability and synaptic transmission. This mechanism is thought to contribute to its therapeutic effects.
Approved indications
- Treatment-resistant schizophrenia
Common side effects
- Nausea
- Dizziness
- Headache
Key clinical trials
- ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC) (PHASE2)
- ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC) (PHASE2)
- ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALKS 37 CI brief — competitive landscape report
- ALKS 37 updates RSS · CI watch RSS
- Alkermes, Inc. portfolio CI